Swiss Life Asset Management’s Abiomed Inc ABMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-2,344
Closed -$575K 635
2022
Q3
$575K Sell
2,344
-143
-6% -$38.6K 0.01% 514
2022
Q2
$617K Buy
+2,487
New +$671K 0.01% 513
2021
Q1
Sell
-749
Closed -$243K 534
2020
Q4
$243K Sell
749
-718
-49% -$199K ﹤0.01% 490
2020
Q3
$406K Sell
1,467
-3,513
-71% -$1.01M 0.01% 430
2020
Q2
$1.2M Buy
+4,980
New +$1,000K 0.02% 363
2019
Q3
Sell
-33,219
Closed -$8.65M 552
2019
Q2
$8.65M Buy
33,219
+6,057
+22% +$1.61M 0.1% 138
2019
Q1
$7.76M Buy
+27,162
New +$9.03M 0.1% 142
2018
Q4
Sell
-8,892
Closed -$4M 490
2018
Q3
$4M Buy
8,892
+4,962
+126% +$1.96M 0.05% 214
2018
Q2
$1.61M Buy
+3,930
New +$1.42M 0.02% 335

Other funds holding ABMD

Swiss Life Asset Management's ABMD Position: Q4 2022 in Review

Swiss Life Asset Management sold out of Abiomed Inc (ABMD) in Q4 2022, closing a stake of 2,344 shares — an estimated $575K sold.

Swiss Life Asset Management first reported a position in ABMD in Q2 2018 and held it in 9 quarters. The position peaked at $8.65M in Q2 2019. 8 funds tracked by Wall St. Rank hold ABMD as of Q4 2022.

  • Swiss Life Asset Management reported no remaining Abiomed Inc position as of Q4 2022 after selling out during the quarter.
  • Swiss Life Asset Management sold 2,344 Abiomed Inc shares in Q4 2022, an estimated $575K.
  • Swiss Life Asset Management first reported a position in Abiomed Inc in Q2 2018 and held it in 9 quarters.
  • Swiss Life Asset Management's Abiomed Inc position peaked at $8.65M in Q2 2019.
  • 8 funds tracked by Wall St. Rank held Abiomed Inc as of Q4 2022.

Based on Swiss Life Asset Management's 13F filing for Q4 2022, filed 9 Dec 2025.